| Code | CSB-RA009438MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to maridebart, targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). GIPR is a G protein-coupled receptor primarily expressed in pancreatic beta cells, adipose tissue, and bone, where it mediates the effects of the incretin hormone GIP. Upon activation, GIPR stimulates insulin secretion in a glucose-dependent manner, influences lipid metabolism, and plays a role in energy homeostasis. Dysregulation of GIPR signaling has been implicated in metabolic disorders including type 2 diabetes and obesity, making it an important therapeutic target for metabolic disease research.
Maridebart is a clinical-stage therapeutic antibody designed as a GIPR antagonist, being investigated for its potential in treating obesity and metabolic syndrome by modulating incretin receptor pathways. This biosimilar antibody provides researchers with a valuable tool for investigating GIPR biology, studying incretin-based mechanisms, exploring metabolic pathway interactions, and supporting preclinical studies in diabetes and obesity research. It enables detailed examination of GIPR function in various experimental models and cellular systems.
There are currently no reviews for this product.